Intrexon, a US-based synthetic biology company, has closed its series E round at $100m, bringing the company’s total capital raised to more than $259m. New investors took the majority of the round while existing investors, including billionaire Randal Kirk, Intrexon’s executive chairman, through his Third Security venture investment unit, and Sandbox Industries, a venture capital…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
